MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alexza Pharmaceuticals Company Profile (NASDAQ:ALXA)

Consensus Ratings for Alexza Pharmaceuticals (NASDAQ:ALXA) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Alexza Pharmaceuticals (NASDAQ:ALXA)
Show:
DateFirmActionRatingPrice TargetActions
3/27/2015Roth CapitalSet Price TargetHold$2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Alexza Pharmaceuticals (NASDAQ:ALXA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/11/2016Q116($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/28/2016Q415($0.37)($0.15)$1.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.34)($0.27)$1.60 million$1.77 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.60)($0.63)$1.49 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.51)($0.02)$3.36 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2015Q414($0.68)($0.35)$2.99 million$1.45 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q3($0.74)($0.77)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.67)($0.34)$2.24 million$1.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014Q1($0.55)($0.55)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.54)($0.72)$1.98 million$2.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013$0.09($0.21)$14.17 million$40.84 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.45)($1.31)$1.00 million$0.73 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.52)$1.86 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Alexza Pharmaceuticals (NASDAQ:ALXA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Alexza Pharmaceuticals (NASDAQ:ALXA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alexza Pharmaceuticals (NASDAQ:ALXA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/21/2016Ferrer Internacional S GrupoMajor ShareholderBuy19,465,714$0.90$17,519,142.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Gordon RingoldDirectorBuy10,000$4.77$47,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013Thomas Braxton KingCEOBuy40,000$4.48$179,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013Thomas Braxton KingCEOBuy40,000$4.48$179,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/18/2013Lansdowne Partners Austria GmbMajor ShareholderSell125,000$4.75$593,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/27/2012Lansdowne Partners Austria GmbMajor ShareholderBuy72,189$4.85$350,116.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2012James V CassellaEVPSell4,558$4.90$22,334.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Alexza Pharmaceuticals (NASDAQ:ALXA)
DateHeadline
06/22/16 02:27 PMGrupo Ferrer to Acquire Alexza Pharma (ALXA) for 90c/Share
06/22/16 12:04 PMALEXZA PHARMACEUTICALS INC. Financials -
06/21/16 07:55 AMALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisti -
06/21/16 07:00 AMAlexza Pharmaceuticals Acquired by Ferrer - [PR Newswire] - MOUNTAIN VIEW, Calif. and BARCELONA, Spain, June 21, 2016 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (OTC: ALXA, "Alexza") and Grupo Ferrer Internacional, S.A. ("Ferrer") today announced ...
06/17/16 02:25 PMALEXZA PHARMACEUTICALS INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
06/16/16 03:10 PMALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or -
06/01/16 11:51 AMAlexza Pharmaceuticals, Inc. :ALXA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/16/16 09:10 PMINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm for Additional Information - [Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Alexza Pharmaceuticals, Inc.
05/16/16 12:01 PMALEXZA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Ferrer Pharma, Inc. May be Unfair to Shareholders - [Business Wire] - Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Alexza Pharmaceuticals, Inc.
05/13/16 10:15 PMSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information - [Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Alexza Pharmaceuticals, Inc.
05/13/16 03:04 PMALEXZA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report -
05/13/16 09:59 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Alexza Pharmaceuticals, Inc. to Ferrer Pharma, Inc. - ALXA - [Accesswire] - NEW YORK, NY / ACCESSWIRE / May 13, 2016 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) stock ...
05/12/16 09:15 PMSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Alexza Pharmaceuticals, Inc. -ALXA - [PR Newswire] - BALA CYNWYD, Pa., May 12, 2016 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Alexza Pharmaceuticals, Inc. ("Alexza" or "the Company") (Nasdaq- ALXA-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Ferrer Pharma, Inc ("Ferrer Pharma"). For example, Alexza stock traded at $5.00 per share on July 22, 2014 and an analyst has set a price target on Alexza stock at $1.25 per share.
05/11/16 04:17 PMAlexza Reports 2016 First Quarter Financial Results - [at noodls] - MOUNTAIN VIEW, Calif., May 11, 2016/PRNewswire / -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, 'Alexza', or the 'Company') today reported financial results for the quarter ended March 31, 2016. The net ...
05/11/16 06:07 AMQ1 2016 Alexza Pharmaceuticals Inc Earnings Release - After Market Close -
05/10/16 02:59 PMWhy is Alexza Pharmaceuticals (ALXA) Stock Soaring Today? -
05/10/16 07:48 AMAlexza to Cancel 2016 First Quarter Financial Results Earnings Call - [at noodls] - MOUNTAIN VIEW, Calif., May 10, 2016/PRNewswire / -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, 'Alexza', or the 'Company') today announced that it intends to issue a press release reporting financial ...
05/10/16 05:15 AMALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material -
04/26/16 11:10 AMAlexza Pharmaceuticals, Inc. (ALXA) Broker Price Targets For The Coming Week - Share Trading News - Alexza Pharmaceuticals, Inc. (ALXA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Alexza Pharmaceuticals, Inc. (ALXA). The latest reports which are currently in issue on Sunday 24th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...
04/26/16 11:10 AMWorst Performing Industries For April 26, 2016 - Benzinga - Worst Performing Industries For April 26, 2016BenzingaDrug Manufacturers - Other: This industry declined 1.3 percent by 11:00 am with Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) moving down 7.9 percent. Alexza Pharmaceuticals shares have declined 69.23 percent over the past 52 weeks, while the S&P ...and more »
04/22/16 11:00 AMLatest Analyst Ratings For Alexza Pharmaceuticals, Inc. (ALXA) - Share Trading News - Latest Analyst Ratings For Alexza Pharmaceuticals, Inc. (ALXA)Share Trading NewsAlexza Pharmaceuticals, Inc. has a 50 day moving average of 0.53 and a 200 day moving average of 0.71. The stock's market capitalization is 11.55M, it has a 52-week low of 0.22 and a 52-week high of 2.05. The share price of the company (ALXA) was down ...Alexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Short Interest Increased By 3.22%Franklin Independentall 2 news articles »
04/22/16 11:00 AMAlexza Pharmaceuticals, Inc. (ALXA) – Broker Update - Risers & Fallers - Alexza Pharmaceuticals, Inc. (ALXA) – Broker UpdateRisers & FallersAlexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. The Company's product candidates are based ...
04/15/16 01:53 PMBroker Roundup For Alexza Pharmaceuticals, Inc. (ALXA) - Share Trading News - Broker Roundup For Alexza Pharmaceuticals, Inc. (ALXA)Share Trading News03/31/2014 – Alexza Pharmaceuticals, Inc. had its “positive” rating reiterated by analysts at Edison Group. The share price of Alexza Pharmaceuticals, Inc. (ALXA) was up +5.66% during the last trading session, with a day high of 0.58. 80079 shares were ...Alexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Short Interest Increased By 3.22%SmallCapWired.comStock Activity Watchlist: Invacare Corporation (NYSE:IVC), Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Foresight ...Property Mentorall 3 news articles »
04/12/16 01:48 PMAlexza Pharmaceuticals, Inc. (ALXA) Latest Broker Coverage - Risers & Fallers - Alexza Pharmaceuticals, Inc. (ALXA) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Alexza Pharmaceuticals, Inc. (ALXA). According to the latest broker reports outstanding on Monday 11th of April, 1 analyst has a rating of “strong buy”, 0 analysts ...Alexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Shorts Decreased by 23.66% After Short CoveringRiversideGazette.comall 2 news articles »
04/12/16 01:48 PMAnalyst Coverage: Alexza Pharmaceuticals, Inc. (ALXA) - Risers & Fallers - Analyst Coverage: Alexza Pharmaceuticals, Inc. (ALXA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Alexza Pharmaceuticals, Inc. (ALXA). The latest broker reports which are currently outstanding on Tuesday 12th of April state 1 analyst has a rating of “strong buy”, 0 ...
04/08/16 02:02 PMAlexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Shorted Shares Decreased By 23.66% - Stock Caller - Alexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Shorted Shares Decreased By 23.66%Stock CallerThe short interest to Alexza Pharmaceuticals Incorporated's float is 2.83%. The stock is up 7.69% or $0.04 after the news, hitting $0.56 per share. About 1,409 shares traded hands. Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) has declined 53.98% since ...and more »
04/02/16 01:45 PMAlexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Shorts Decreased by 23.66% After Short Covering - Clinton Financial - Alexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Shorts Decreased by 23.66% After Short CoveringClinton FinancialThe short interest to Alexza Pharmaceuticals Incorporated's float is 2.83%. The stock decreased 5.00% or $0.025 on March 31, hitting $0.484. Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) has declined 57.14% since August 25, 2015 and is downtrending.
03/30/16 12:04 PMAlexza Pharmaceuticals, Inc. :ALXA-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/30/16 10:47 AMAlexza Pharmaceuticals, Inc. :ALXA-US: Earnings Analysis: 2015 By the Numbers -
03/28/16 03:22 PMAlexza Reports Fourth Quarter and Year End 2015 Financial Results - [at noodls] - MOUNTAIN VIEW, Calif., March 28, 2016/PRNewswire / -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, 'Alexza', or the 'Company') today reported financial results for the quarter and year ended December 31, ...
03/28/16 06:07 AMQ4 2015 Alexza Pharmaceuticals Inc Earnings Release - After Market Close -
03/24/16 03:14 PMALEXZA PHARMACEUTICALS INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements an -
03/15/16 04:00 PMAlexza to Report 2015 Year End Financial Results and Provide Company Update on Monday, March 28, 2016 - [PR Newswire] - Alexza Pharmaceuticals is focused on the research, development, and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products and development pipeline are based on the Staccato® system, a hand-held inhaler designed to deliver a pure drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner. Active pipeline product candidates include AZ-002 (Staccato alprazolam) for the management of epilepsy in patients with acute repetitive seizures and AZ-007 (Staccato zaleplon) for the treatment of patients with middle of the night insomnia. ADASUVE® is Alexza's first commercial product and is currently available in 20 countries. The product is approved for sale by the U.S. Food and Drug Administration, the European Commission and in several Latin American countries. Grupo Ferrer Internacional SA is Alexza's commercial partner for ADASUVE in Europe, Latin America, the Commonwealth of Independent States countries, the Middle East and North Africa countries, Korea, Philippines and Thailand.
03/15/16 11:56 AMAlexza Pharmaceuticals Inc (NASDAQ:ALXA) 2015 Q3 Institutional Investor Sentiment Steady - RiversideGazette.com - Alexza Pharmaceuticals Inc (NASDAQ:ALXA) 2015 Q3 Institutional Investor Sentiment SteadyRiversideGazette.comAlexza Pharmaceuticals Inc (NASDAQ:ALXA) institutional sentiment increased to 1 in 2015 Q3. Its up 0.20, from 0.8 in 2015Q2. The ratio is more positive, as 8 investment managers increased or started new positions, while 10 decreased and sold their ...Running Stocks: Amarin Corporation plc (NASDAQ:AMRN), Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Achillion ...Property Mentorall 13 news articles »
03/14/16 08:56 AMAlexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Sellers Covered 4.31% of Their Shorts - RiversideGazette.com - Alexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Sellers Covered 4.31% of Their ShortsRiversideGazette.comThe short interest to Alexza Pharmaceuticals Incorporated's float is 3.71%. The stock decreased 3.74% or $0.02 on March 11, hitting $0.51. Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) has declined 50.49% since August 6, 2015 and is downtrending.Running Stocks: Amarin Corporation plc (NASDAQ:AMRN), Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Achillion ...Property Mentorall 2 news articles »
03/09/16 04:00 PMAlexza Pharmaceuticals Receives Positive Nasdaq Listing Determination - [PR Newswire] - MOUNTAIN VIEW, Calif., March 9, 2016 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza, or the "Company') announced today that on March 7, 2016 the Nasdaq Listing Qualifications ...
02/28/16 01:01 PMAlexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Shorted Shares Increased By 14.5% - Clinton Financial - Alexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Shorted Shares Increased By 14.5%Clinton FinancialThe short interest to Alexza Pharmaceuticals Incorporated's float is 3.88%. The stock increased 7.60% or $0.021 on February 26, hitting $0.296. About 25,574 shares traded hands. Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) has declined 72.38% since ...and more »
02/28/16 01:01 PMAlexza Pharmaceuticals Confirms Grupo Ferrer Non-binding LoI - Benzinga - Alexza Pharmaceuticals Confirms Grupo Ferrer Non-binding LoIBenzingaThe entering into the Letter of Intent follows exploration of strategic options that the Company announced previously. On September 28, 2015, the Company announced that it had retained Guggenheim Securities, LLC to assist in exploring strategic options ...
02/26/16 07:55 PMAlexza Pharmaceuticals Confirms Grupo Ferrer Non-binding Letter Of Intent - MOUNTAIN VIEW, Calif., Feb. 26, 2016 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza, or the "Company') announced today that on February 15, 2016 it had entered into a non-binding letter of intent (the "Letter of Intent") with Grupo ...
02/24/16 01:40 PMAlexza Pharma (ALXA) Reacquires ADASUVE Rights from Teva - StreetInsider.com - Alexza Pharma (ALXA) Reacquires ADASUVE Rights from TevaStreetInsider.comAlexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has reacquired U.S. commercial rights for ADASUVE® (loxapine) inhalation powder from Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ: ...and more »
02/24/16 08:09 AMALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi -
02/24/16 07:02 AM8:02 am Alexza Pharma reacquired rights for ADASUVE inhalation powder from Teva Pharmaceuticals (TEVA) sub; offers shares to TEVA in exchange for $5 mln note reduction -
02/24/16 07:00 AMAlexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE® (loxapine) inhalation powder - [PR Newswire] - MOUNTAIN VIEW, Calif., Feb. 24, 2016 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has reacquired U.S. commercial rights for ADASUVE ® (loxapine) inhalation powder ...
02/13/16 11:59 AMAlexza Pharmaceuticals Inc. (ALXA) - Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions worldwide. The company s product candidates are based ...
02/11/16 12:04 PMAnalyst Coverage Updates - Alexza Pharmaceuticals, Inc. (ALXA) - Risers & Fallers - Analyst Coverage Updates - Alexza Pharmaceuticals, Inc. (ALXA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Alexza Pharmaceuticals, Inc. (ALXA). The latest broker reports which are currently outstanding on Thursday 11th of February state 1 analyst has a rating of “strong buy”, ...
02/06/16 11:41 AMAlexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Short Interest Increased By 5.69% - fdanewsalert.com - Alexza Pharmaceuticals Incorporated (NASDAQ:ALXA) Short Interest Increased By 5.69%fdanewsalert.comThe short interest to Alexza Pharmaceuticals Incorporated's float is 3.77%. The stock is up 8.33% or $0.025 after the news, hitting $0.325 per share. About 83,368 shares traded hands. Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) has declined 71.70% since ...and more »
02/04/16 11:12 AMPrice Target Update On Alexza Pharmaceuticals, Inc. (ALXA) - Risers & Fallers - Price Target Update On Alexza Pharmaceuticals, Inc. (ALXA)Risers & FallersThe share price of Alexza Pharmaceuticals, Inc. (ALXA) was down -6.39% during the last trading session, with a day high of 0.33. 76997 shares were traded on Alexza Pharmaceuticals, Inc.'s last session. The stock's 50 day moving average is 0.56 and its ...Alexza Pharmaceuticals, Inc. (ALXA) Stock Rating Lowered by Zacks Investment ResearchFinancial Market Newsall 2 news articles »
01/26/16 11:08 AMSwing Stocks: Alexza Pharmaceuticals (NASDAQ:ALXA), Clearwater Paper Corporation (NYSE:CLW), Biogen ... - Gaining Green (press release) (registration) (blog) - Swing Stocks: Alexza Pharmaceuticals (NASDAQ:ALXA), Clearwater Paper Corporation (NYSE:CLW), Biogen ...Gaining Green (press release) (registration) (blog)Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) ended the last trading day at $0.40. Company weekly volatility is calculated as 18.11% and price to cash ratio as 0.69. Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) showed a weekly performance of -10.71%.and more »
12/29/15 08:30 AMNew Strong Buy Stocks for December 29th -
12/24/15 08:30 AMNew Strong Buy Stocks for December 24th -
About Alexza Pharmaceuticals

Alexza Pharmaceuticals logoAlexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. The Company's product candidates are based on its technology the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled allows for systemic drug delivery. It has two product candidates in active development, AZ-002 and AZ-007. Its product AZ-002 contains Staccato alprazolam as an active ingredient. AZ-002 is indicated for the treatment of Acute Repetitive Seizures. It initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy. Its product AZ-007 contains Staccato zaleplon as an active ingredient. It is developing AZ-007 for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening who have difficulty falling back asleep.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALXA
  • CUSIP:
Key Metrics:
  • Previous Close: $0.94
  • 50 Day Moving Average: $0.904
  • 200 Day Moving Average: $0.632
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $20.34M
  • Current Quarter EPS Consensus Estimate: $-2.110 EPS
Additional Links:
Alexza Pharmaceuticals (NASDAQ:ALXA) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha